CTLA4 and renal cell carcinoma: Ipilimumab is an anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) approved for the treatment of advanced melanoma and renal cell carcinoma and is also under clinical investigation in multiple adult and pediatric cancers (26).